Şizofreni kronik ve yeti yitimine yol açan bir hastalıktır. Özellikle ilk psikotik atağını geçiren şizofreni hastalarında uygulanan tedaviye yeterli yanıt elde edilebilmesi, hastalığın gidişinin belirlenmesi açısından önemlidir. Antipsikotik ilaçlarla tedaviye verilen yanıtın yordanabilmesi, gereksiz ilaç kullanımını azaltıp, tedaviye uyumu arttırarak, etkin bir klinik yanıt elde edilebilmesine olanak tanır. Bu bağlamda konunun önemi göz önünde bulundurularak ilk atak şizofreni hastalarında antipsikotik tedaviye yanıtı belirleyen yordayıcı faktörlerle ilgili olarak bu derleme düzenlenmiştir. Bu derleme için Pubmed veri tabanında elektronik arama yapılmıştır. Bu alanda yapılan çalışmalarda gerek farmakolojik, nörogörüntüleme ve elektroensefalografi (EEG) bulgularını içeren biyolojik, gerek tedavi edilmemiş psikoz süresi, tedavide kullanılan antipsikotik ajanlar, siliknörolojik belirtiler, psikotik belirti türü ve şiddeti ile frontal lob işlevinin nörofizyolojik belirtecini (NoGo- Anteriorization, NGA) içeren klinik değişkenlerle ilaç tedavisine yanıt arasında değişik bağlantılar kurulmuş olmakla beraber daha ileri klinik çalışmalara gereksinim olduğu sonucuna varılmıştır .
Schizophrenia is an illness which is chronic that leads todisability. Particularly obtaining sufficient treatmentresponse in patients with first episode schizophrenia isimportant in determining the course of the illness.Predicting treatment response with antipsychotic drugswould allow to obtain efficient clinical response byreducing unnecessary drug use and enhance the adherence to treatment. In this context, considering theimportance of topic, this review is written out relevant topredictive factors of antipsychotic treatment response inpatients with first episode schizophrenia. Electronicsearch was conducted for this review in Pubmed database. Although there are varied links between drugresponse and both biological, including pharmacological, neuroimaging and electroencephalography (EEG)findings, and clinical, including duration of untreatedpsychosis, antipsychotic agents which are used in treatment, soft neurological signs, kind and severity of psychotic symptoms and neurophysiologic indicator offrontal lobe function (NoGo Anteriorization, NGA), variables in studies which are conducted in this field, thereis a need for further studies as a conclusion
Addington J, Van Mastrigt S, Addington D (2004) Duration of untreated psychosis: impact on 2 year outcome. Psychol Med 34 (2): 277-284.
Almoguera B, Riveiro-Alvarez R, Lopez-Castroman J ve ark. (2013) CYP2D6 poor metabolizer status might be associated with better response to risperidone treatment. Pharmacogenetics and Genomics 23 (11): 627-630.
Arranz B, Rosel P, San L ve ark. (2007) Low baseline serotonin- 2A receptors predict clinical response to olanzapine in first- episode schizophrenia patients. Psychiatry Res 153 (2): 103-109. Murri MB, Pariante CM, Dazzan P ve ark. (2012) Hypothalamic-pituitary-adrenal axis and clinical symptoms in first-episode psychosis. Psychoneuroendocrinology 37 (5): 629- 644.
Bottlender R, Sato T, Jäger M ve ark. (2003) The impact of the duration of untreated psychosis prior to first psychiatric admis- sion on the 15 year outcome in schizophrenia. Schizophr Res 62 (1-2): 37-44.
Cesková E, Prikryl R, Kaspárek T ve ark. (2005) Psychopathology and treatment responsiveness of patients with first-episode schizophrenia. Neuropsychiatr Dis Treat 1 (2): 179- 185.
Crespo-Facorro B, Ortiz-Garcia de la Foz V, Ayesa-Arriola R ve ark. (2013) Prediction of acute clinical response following a first episode of non affective psychosis: Results of a cohort of 375 patients from the Spanish PAFIB study. Progress in Neuro- Psychopharmacology & Biological Psychiatry 44 : 162-167.
Dolzan V, Serretti A, Mandelli L ve ark. (2008) Acute antipsy- chotic efficacy and side effects in schizophrenia: association with serotonin transporter promoter genotypes. Prog Neuropsychopharmacol Biol Psychiatry 32 (6): 1562-1566
Drago A, Giegling I, Schäfer M ve ark. (2012) AKAP13, CACNA1, GRIK4 and GRIA1 genetic variations may be asso- ciated with haloperidol efficacy during acute treatment. Eur Neuropsychopharmacol 23 (8): 887-894.
Ehlis AC, Pauli P, Herrmann MJ ve ark. (2012) Hypofrontality in schizophrenic patients and its relevance for the choice of antipsychotic medication: an event related potential study. World J Biol Psychiatry 13 (3): 188-99.
Frangou S, Byrne P (2000) How to manage the first episode of schizophrenia. BMJ 321 (7260): 522-523.
Ganzola R, Maziade M ve Duchesne S (2014) Hippocampus and amygdala volumes in children and young adults at high-risk of schizophrenia: Research synthesis. Schizophr Res 156 (1): 76- 86.
Gao S, Hu Z, Cheng J ve ark. (2012) Impact of catechol-o- methyltransferase polymorphisms on risperidone treatment for schizophrenia and its potential clinical significance. Clin Biochem 45 (10-11): 787-792.
Garner B, Berger GE, Nicolo JP ve ark. (2009) Pituitary volume and early treatment response in drug-naïve first-episode psy- chosis patients. Schizophr Res 113 (1): 65-71.
Grossman I, Sullivan PF, Walley N ve ark. (2008) Genetic deter- minants of variable metabolism have little impact on the clinical use of leading antipsychotics in the CATIE study. Genet Med 10 (10): 720-729.
Gupta M, Moily N, Kaur H ve ark. (2013) Identifying a predic- tive model for response to atypical antipsychotic monotherapy treatment in south Indian schizophrenia patients. Genomics 102 (2): 131-135.
Ikeda M, Yamanouchi Y, Kinoshita Y ve ark. (2008) Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophre- nia. Pharmacogenomics 9 (10): 1437-1443.
Jäger M, Riedel M, Messer T ve ark. (2007) Psychopathological characteristics and treatment response of first episode com- pared with multiple episode schizophrenic disorders. Eur Arch Psychiatry Clin Neurosci 257 (1): 47-53.
Kapur S, Zipursky R, Jones C ve ark. (2000) Relationship between dopamine D2 occupancy, clinical response and side effects: a double blind PET study of first-episode schizophrenia. Am J Psychiatry 157 (4): 514-520.
Kohlrausch FB, Gama CS, Lobato MI ve ark. (2008) Naturalistic pharmacogenetic study of treatment resistance to typical neuroleptics in European-Brazilian schizophrenics. Pharmacogenet. Genomics 18 (7): 599-609.
Lambert M, Naber D, Huber CG (2008) Management of incom- plete remission and treatment resistance in first-episode psy- chosis. Expert Opin Pharmacother 9 (12): 2039-2051.
Lencz T, Robinson DG, Xu K ve ark. (2006) DRD2 promoter region variation as a predictor of sustained response to antipsy- chotic medication in first-episode schizophrenia patients. Am J Psychiatry 163 (3):529-531.
Levine SZ, Leucht S. (2010) Elaboration on the Early-Onset Hypothesis of Antipsychotic Drug Action: Treatment Response Trajectories. Biol Psychiatry 68 (1): 86-92.
Levine SZ, Rabinowitz J, Faries D ve ark. (2012) Treatment response trajectories and antipsychotic medications: Examination of up to 18 months of treatment in the CATIE chronic schizophrenia trial. Schizophr Res 137 (1-3): 141-146.
Li Z, Hu M, Zong X ve ark. (2015) Association of telomere length and mitochondrial DNA copy number with risperidone treatment response in first-episode antipsychotic naïve schizo- phrenia. Sci Rep Dec 18; 5:18553.
Lieberman JA, Tollefson G, Tohen M ve ark. (2003) Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry 160 (8): 1396-1404.
Merlo MC, Kleinlogel H, Koukkou M. (1998) Differences in the EEG profiles of early and late responders to antipsychotic treat- ment in first-episode, drug-naive psychotic patients. 30 (3): 221- 228.
Nenadic I, Dietzek M, Schönfeld N ve ark. (2015) Brain struc- ture in people at ultra-high risk of psychosis, patients with first episode schizophrenia and healthy controls: a VBM study. Schizophr Res 161 (2-3): 169-176.
Nordon C, Rouillon F, Azorin JM ve ark. (2014) Trajectories of antipsychotic response in drug-naive schizophrenia patients: results from the 6-month ESPASS follow-up study. Acta Psychiatr Scand 129 (2): 116-125.
Palaniyappan L, Marques TR, Taylor H ve ark. (2013) Cortical folding defects as markers of poor treatment response in first- episode psychosis. JAMA Psychiatry 70 (10): 1031-1040.
Pelayo-Terán JM, Pérez-Iglesias R, Vázquez-Bourgon J ve ark. (2011) Catechol-O-methyltransferase Val158Met polymorphism and negative symptoms after acute antipsychotic treatment in first-episode non-affective psychosis. Psychiatry Res 185 (1-2): 286-289.
Prikryl R, Ceskova E, Kasparek T ve ark. (2007) Neurological soft signs and their relationship to 1 year outcome in first- episode schizophrenia. Eur Psychiatry 22 (8): 499-504.
Ramsey TL, Liu Q, Massey BW ve ark. (2013) Genotypic varia- tion in the SV2C gene impacts response to atypical antipsy- chotics the CATIE Study. Schizophr Res 149 (1-3) : 21-25.
Sarpal DK, Argyelan M, Robinson DG ve ark. (2016) Baseline Striatal Functional Connectivity as a predictor of response to antipsychotic drug treatment Am J Psychiatry 173 (1): 69-77.
Schennach-Wolff R, Jäger M, Mayr A ve ark. (2011) Predictors of response and remission in the acute treatment of first-episode schizophrenia patients-is it all about early response? Eur Neuropsychopharmacol 21 (5): 370-378.
Schennach R, Meyer S, Seemüller F ve ark. (2012) Response trajectories in 'real world' naturalistically treated schizophrenia patients. Schizophr Res 139 (1-3): 218-224.
Schennach R, Riedel M, Musil R ve ark. (2012) Treatment response in first-episode schizophrenia. Clin Psychopharmacol Neurosci. 10 (2): 78-87.
Stauffer V, Case M, Kollack-Walker S ve ark. (2011) Trajectories of response to treatment with atypical antipsychotic medication in patients with schizophrenia pooled from 6 double blind, ran- domized clinical trials. Schizophr Res 130 (3): 11-19.
Szeszko PR, Narr KL, Phillips OR ve ark. (2012) Magnetic res- onance imaging predictors of treatment response in first episode schizophrenia. Schizophr Bull 38 (3): 569-578.
Vazquez-Bourgon J, Arranz MJ, Mata I ve ark. (2010) Serotonin transporter polymorphisms and early response to antipsychotic treatment in first episode of psychosis. Psychiatry Res 175 (3): 189-194.